Overview
Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus
Status:
Terminated
Terminated
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with mitomycin, doxorubicin, and cisplatin in treating patients with recurrent or advanced cancer of the uterus.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Gynecologic Oncology GroupCollaborator:
National Cancer Institute (NCI)Treatments:
Cisplatin
Doxorubicin
Liposomal doxorubicin
Mitomycin
Mitomycins
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed advanced, persistent, or recurrentuterine sarcoma Documented disease progression after local therapy Measurable disease
consisting of abdominal, pelvic, chest, or other masses that can be defined in at least two
dimensions by palpation, x-ray, computed tomography or ultrasound
PATIENT CHARACTERISTICS: Age: No age specified Performance status: Karnofsky 50%-100% Life
expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Granulocyte count at least
1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times
normal SGOT no greater than 3 times normal Alkaline phosphatase no greater than 3 times
normal Renal: Creatinine no greater than 1.5 times normal Cardiovascular: Ejection fraction
within institutional normal limits Pulmonary: Not specified Other: No active infection No
concurrent second malignancy other than nonmelanoma skin cancer Must be disease free of any
prior malignancy for at least 5 years and not received any treatments with chemotherapy or
radiation therapy for that malignancy
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 6 weeks since
radiotherapy Recovered from effects of radiotherapy Surgery: Recovered from effects of
surgery